We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Omega Diagnostics Group Plc | LSE:ODX | London | Ordinary Share | GB00B1VCP282 | ORD 4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.20 | 2.00 | 2.40 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMODX
RNS Number : 1757A
Omega Diagnostics Group PLC
17 January 2020
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Nigerian Ministry of Health approval for VISITECT(R) CD4 350 test
Omega (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing, announces that the Company has received approval from the Federal Ministry of Health ("MOH") to enable the VISITECT(R) CD4 350 test to be deployed in Nigeria.
Following a product evaluation in six geopolitical zones in Nigeria, co-ordinated by the National AIDS and Sexually Transmitted Infections Control Programme ("NASCP"), NASCP recommended to the MOH that the Company's VISITECT(R) CD4 350 test be adopted into the National HIV Control Programme as a rapid and instrument-free test device that provides actionable results at the point of care.
MOH approval means the Company's VISITECT(R) CD4 350 test is the first rapid and instrument-free CD4 test to be implemented throughout Nigeria in the care of people living with HIV. As announced on 2 December 2019, we have received initial orders from our distribution partner in Nigeria for 250,000 tests and we will now look to firm up a delivery schedule to determine what proportion of this demand can be shipped prior to the end of the financial year.
Colin King, CEO of Omega commented: "I am pleased that our test has been approved for use in Nigeria which was one of our key strategic aims and allows our unique point-of-care test to make a real difference to people living with HIV in Nigeria."
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
Contacts:
Omega Diagnostics Group PLC Tel: 01259 763 030 Bill Rhodes, Interim Non-Executive www.omegadiagnostics.com Chairman Colin King, Chief Executive Kieron Harbinson, Group Finance Director finnCap Ltd Tel: 020 7220 0500 Geoff Nash/Hannah Boros (Corporate Finance) Camille Gochez (ECM) Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com Paul McManus Mob: 07980 541 893 Lianne Cawthorne Mob: 07584 391 303
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCZZGMMGNZGGZM
(END) Dow Jones Newswires
January 17, 2020 05:30 ET (10:30 GMT)
1 Year Omega Diagnostics Chart |
1 Month Omega Diagnostics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions